X0609 4 2026-05-19 0 0001728328 InMed Pharmaceuticals Inc. INM 0001940272 ADAR1 Capital Management, LLC false 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738 0 0 1 0 0001861120 Schneeberger Daniel false 3503 WILD CHERRY DRIVE, BUILDING 9 AUSTIN TX 78738 0 0 1 0 0 Common Shares 2026-05-19 4 P 0 68551 1.5998 A 400000 I See Footnote Common Shares 2026-05-19 4 P 0 200000 1.5604 A 600000 I See Footnote Common Shares 2026-05-19 4 P 0 200000 1.499 A 800000 I See Footnote The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5700 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.5100 to $1.6000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.4350 to $1.5700, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. ADAR1 Capital Management, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger 2026-05-21 /s/ Daniel Schneeberger 2026-05-21